在癌细胞中准氧化还原敏感的MBD2-NuRD凝聚物
Heyang Wei1, Hongdan Zheng1, Siqing Wang1
1Department of Neurosurgery, Huashan Hospital, the Shanghai Key Laboratory of Medical Epigenetics, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Biomedical Sciences, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Nature cell biology
|April 30, 2025
概括
甲基-CpG结合域蛋白2 (MBD2) 形成核凝结物,通过沉默瘤抑制基因来驱动癌症生长. 通过氧化应激破坏这些凝结物会阻碍瘤的进展.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 通过高甲基化对瘤抑制基因的转录性沉默是癌症的一个关键事件.
- 驱动这种沉默的精确机制在很大程度上是未知的.
研究的目的:
- 阐明甲基-CpG结合域蛋白2 (MBD2) 在转录基因沉默在瘤发生过程中的作用.
- 调查针对癌症治疗的MBD2凝聚物的潜力.
主要方法:
- 利用多种癌细胞系研究MBD2凝结物的形成和功能.
- 研究了MBD2和NuRD复合体之间的相互作用.
- 评估了MBD2凝析物破坏对染色质结构和基因表达的影响.
- 检查了MBD2凝析物的氧化还原敏感性和亲氧化干预的效果.
主要成果:
- MBD2在癌细胞中形成核凝聚物,招募NuRD复合体来沉默瘤抑制基因并促进瘤生长.
- 破坏MBD2凝聚物导致NuRD复合蛋白减少,异色染色体不稳定,染色体放松,从而抑制瘤的进展.
- MBD2凝聚物形成对氧化还原有敏感性,具有亲氧化处理分散凝聚物和减轻基因抑制.
结论:
- MBD2核冷凝剂在维持癌细胞增殖所必需的抑制性染色质状态方面发挥着至关重要的作用.
- 通过氧化应激向MBD2凝聚物为特征为过度MBD2凝聚物形成的癌症提供了潜在的治疗策略.
相关概念视频
Electron Transport Chain: Complex I and II
9.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.6K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K


